Q1 Mixed Financials
Sharda Cropchem Posts Mixed Q1 FY27: Revenue Grows 9%, Profit Declines
Anonymous
Key Points
1
The board met on July 29, 2026 and approved the unaudited standalone and consolidated quarterly results after a limited review by B S R & Co. LLP, which issued an unmodified opinion, reinforcing regulatory compliance and transparency.
2
Sharda Cropchem published an investor/analyst presentation detailing its Q1 FY27 unaudited results and submitted it to both the NSE and BSE; the presentation is also available on the company's website to enhance accessibility for investors and analysts.
3
Consolidated Q1 FY27 revenue rose 9% year-on-year to ₹1,074 crore and EBITDA increased 25% to ₹178 crore, with margins at 16.6%; however, profit before and after tax declined due to unusually high forex gains in the base quarter, even as the balance sheet remains debt-free with ₹767 crore in cash and investments.
4
Regional performance was mixed, with NAFTA, LATAM and Rest of World delivering double-digit growth while Europe fell about 11%; the company also highlighted a robust registrations pipeline of 3,016 product registrations, with 1,027 in the pipeline for future launches.
5
Standalone results showed revenue up 17.5% to ₹968.9 crore and net profit up 23.7% to ₹140.6 crore, driven by higher other income (₹107.0 crore), including dividend income from subsidiaries amounting to ₹75.4 crore, underscoring the asset-light model and subsidiary cash flows supporting profitability.
Sharda Cropchem reported a mixed set of numbers for Q1 FY27, with consolidated revenue climbing 9% year-on-year to ₹1,074 crore, while net profit slumped 38% to ₹88 crore, according to ScanX Trade. The board met on July 29, 2026 and approved the unaudited results after a limited review by auditor B S R & Co. LLP, which issued an unmodified opinion.
The profit drop was not driven by weak operations. EBITDA — earnings before interest, tax, depreciation, and amortisation — rose 25% to ₹178 crore, with margins at 16.6%, per TipRanks. Instead, unusually high forex gains in the same quarter last year created a tough base to beat.
Standalone Results Show Sharper Profit Growth of 23.7%
On a standalone basis, the picture looked healthier. Revenue rose 17.5% to ₹968.9 crore, and net profit jumped 23.7% to ₹140.6 crore, according to TipRanks. A big chunk of that profit came from other income of ₹107 crore, which included ₹75.4 crore in dividend income from subsidiaries.
This highlights Sharda Cropchem's asset-light model. The company does not manufacture chemicals itself. Instead, it holds product registrations and sources from third parties. Cash flows from subsidiaries flow back up, boosting standalone profitability even when global margins are squeezed.
NAFTA and Emerging Markets Grow, Europe Drags Performance
Regional performance was uneven across Q1 FY27. NAFTA, Latin America, and Rest of World all delivered double-digit revenue growth. Europe, however, fell about 11%, pulling down the consolidated headline, per TipRanks. Europe is Sharda's largest region, so any dip there has an outsized effect.
The company's registrations pipeline remains a key growth lever. Sharda holds 3,016 active product registrations globally. Another 1,027 registrations are in the pipeline for future launches. These registrations act like licenses — they give Sharda the right to sell specific agrochemical products in specific markets.
Debt-Free Balance Sheet With ₹767 Crore Cash Cushion
Sharda Cropchem enters the rest of FY27 with no debt and ₹767 crore in cash and investments on its balance sheet, according to TipRanks. That financial strength gives the company room to absorb forex swings and cost pressures without taking on borrowings.
Consolidated sales for Q1 FY27 came in at roughly ₹10,737 million, up from ₹9,848 million a year ago, per Market Screener. The company also filed its results and investor presentation simultaneously with both the NSE and BSE, making data available on its website for retail investors and analysts.
Forex Base Effect Masks Solid Operational Recovery
The 38% net profit drop looks alarming, but context matters. In Q1 FY26, Sharda booked large one-time forex gains. Those gains inflated last year's profit figure. This year, without that tailwind, the comparison looks bad even though core operations improved, per ScanX Trade.
EBITDA margin expanded to 16.6% from lower levels a year ago, showing that cost discipline is working. Investors will now watch whether Europe recovers in Q2 and whether the 1,027 pipeline registrations begin converting into revenue. The debt-free balance sheet means Sharda has the firepower to invest in new launches without strain.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
7
Reach
17
Topics
A
AnonymousAuthor
